Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Hofseth BioCare ASA is a Norway-based biotechnology company specializing in the development, manufacturing, marketing, and sale of high-value biomarine ingredients derived from fresh salmon. Its primary function is to produce innovative nutritional products for human health supplements, sports nutrition, clinical nutrition, functional foods, and pet nutrition, utilizing a patented enzymatic hydrolysis process that preserves essential lipids, proteins, bioactive peptides, and micro-components for potential medicinal applications. Key products include OmeGo salmon oil rich in natural fatty acids and omegas; ProGo, a hydrolyzed soluble protein for weight management and metabolism; CalGo, a calcium-collagen complex supporting bone and joint health; CollaGo for collagen benefits; and PetGo non-soluble protein for pets. Headquartered in Ålesund with production in Midsund and global offices in cities like Oslo, London, Chicago, and Tokyo, the company serves markets primarily in Europe, North America, and Asia. With around 75-78 employees, Hofseth BioCare collaborates with leading universities on research into applications for conditions like gastrointestinal disorders and respiratory issues, positioning it as a key player in sustainable marine-derived health solutions.
€0.10
+€0.00 (+0.98%)
EOD Jul 2, 2026
The business is unprofitable at the operating level (-43.79% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 0.4% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -NOK 48M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 256M
▼ -0.4% YoY
Net Income (TTM)
-NOK 135M
▼ -7.6% YoY
Op. Margin
-43.79%
▲ +0.2pp YoY
ROIC
-30.05%
▲ +2.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 48M
▼ -248.5% YoY
Op. Cash Flow (TTM)
-NOK 29M
▼ -150.2% YoY
Net Debt
NOK 297M
Cash & Equiv.
NOK 63M
3Y CAGR: +28.6%
Continue Research
Hofseth BioCare ASA (HBC.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Hofseth BioCare ASA scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Hofseth BioCare ASA scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -43.8% operating margin and a -30.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh HBC.XOSL's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.